Achieve Life Sciences (ACHV) Gains from Investment Securities (2012 - 2026)
Achieve Life Sciences (ACHV) posted Gains from Investment Securities of -$285000.0 for Q1 2026, down 350.0% on a QoQ basis from $114000.0 in Q4 2025, and down 413.19% year-over-year from $91000.0 in Q1 2025.
Achieve Life Sciences (ACHV) Gains from Investment Securities (2012 - 2026) Analysis & Trends
Achieve Life Sciences' Gains from Investment Securities history runs 9 years deep, the most recent figure standing at -$285000.0 for Q1 2026.
- Quarterly Gains from Investment Securities fell 413.19% year-over-year to -$285000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $32000.0 (down 95.15% YoY) and the FY2025 annual result came in at $408000.0, down 34.3% from the prior year.
- Gains from Investment Securities was -$285000.0 for Q1 2026 at Achieve Life Sciences, down from $114000.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $450000.0 in Q4 2024 and bottomed at -$285000.0 in Q1 2026.
- A 3-year average of $82666.7 and a median of $91000.0 in 2025 frame the typical range for Gains from Investment Securities.
- Annual changes were most pronounced in 2025 — Gains from Investment Securities jumped 75.0% — and 2026, when it plunged 413.19%.
- Achieve Life Sciences' Gains from Investment Securities stood at $450000.0 in 2024, then tumbled by 74.67% to $114000.0 in 2025, then slumped by 350.0% to -$285000.0 in 2026.
- Business Quant data shows ACHV's Gains from Investment Securities at -$285000.0 in Q1 2026, $114000.0 in Q4 2025, and $106000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Achieve Life Sciences | 330.17 Mn | 330.17 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -285,000.00 |
| Mar 31, 2026 | -285,000.00 |
| Dec 31, 2025 | 114,000.00 |
| Dec 31, 2025 | 114,000.00 |
| Sep 30, 2025 | 106,000.00 |
| Sep 30, 2025 | 106,000.00 |
| Jun 30, 2025 | 97,000.00 |
| Jun 30, 2025 | 97,000.00 |
| Mar 31, 2025 | 91,000.00 |
| Mar 31, 2025 | 91,000.00 |
| Dec 31, 2024 | 450,000.00 |
| Dec 31, 2024 | 450,000.00 |
| Sep 30, 2024 | 62,000.00 |
| Sep 30, 2024 | 62,000.00 |
| Jun 30, 2024 | 57,000.00 |
| Jun 30, 2024 | 57,000.00 |
| Mar 31, 2024 | 52,000.00 |
| Mar 31, 2024 | 52,000.00 |
| Dec 31, 2017 | -39,000.00 |
| Dec 31, 2017 | -39,000.00 |